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Chen, Donghui, Kun Guo, Jihong Yang, William A.
Frazier, Jeffrey M. Isner, and Vicente Andre´s. Vascular
smooth muscle cell growth arrest on blockade of thrombospon-
din-1 requires p21Cip1/WAF1. Am. J. Physiol. 277 (Heart Circ.
Physiol. 46): H1100–H1106, 1999.—Abnormal proliferation
of vascular smooth muscle cells (VSMCs) is thought to play an
important role in the pathogenesis of atherosclerosis and
restenosis. Previous studies have implicated the extracellular
matrix protein thrombospondin-1 (TSP1) in mitogen-depen-
dent proliferation of VSMCs. In this study, we investigated
the molecular mechanisms involved in TSP1-mediated regu-
lation of VSMC growth. Neutralizing A4.1 anti-TSP1 anti-
body inhibited the activity of the G1/S cyclin-dependent
kinase 2 (cdk2) and blocked the induction of S-phase entry,
which normally occurs in serum-stimulated VSMCs. This
growth-inhibitory effect was associated with a marked induc-
tion of p21Cip1/WAF1 (p21) expression in A4.1-treated VSMCs.
Moreover, addition of A4.1 antibody to VSMCs markedly
increased the level of p21 bound to cdk2. Thus growth arrest
on antibody blockade of TSP1 may be mediated by the cdk
inhibitory protein p21. Consistent with this notion, anti-
TSP1 antibody inhibited [3H]-thymidine incorporation in
wild-type but not in p21-deficient mouse embryonic fibro-
blasts (MEFs). Together, these data suggest that p21 plays an
important role in TSP1-mediated control of cellular prolifera-
tion.
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THE EXTRACELLULAR MATRIX (ECM) plays a critical role
in highly specialized cellular functions, including differ-
entiation, migration, and proliferation (5, 21, 45, 46).
The composition and structure of the ECM differs from
tissue to tissue and can undergo continuous changes
within the same tissue, thereby having both temporal
and spatial effects on cells that come into contact with
it. These changes result in part from the regulation of
the synthesis and secretion of the glycoproteins that
are incorporated into the ECM.
Unlike terminally differentiated myocytes, mature
smooth muscle cells can reenter the cell cycle in re-
sponse to physiopathological stimuli (35). Dedifferentia-
tion and proliferation of vascular smooth muscle cells
(VSMCs) contribute to the pathogenesis of vascular
occlusive disease, including atherosclerosis, restenosis
after angioplasty, and bypass graft occlusion. Inhibition
of VSMC proliferation has been shown to attenuate
restenosis after balloon angioplasty in several animal
models (12, 50). VSMC proliferation induced by growth
factors in vitro and balloon injury in vivo is associated
with changes in the expression of ECM proteins and
their corresponding cellular receptors, which may play
an important role as physiological regulators of cell
cycle progression during atherosclerosis and restenosis
(2). One of the ECM components for which dramatic
regulatory changes have been observed is thrombospon-
din-1 (TSP1), a member of a family of related glycopro-
teins (TSP1 through TSP5) (3, 4, 10, 24, 25, 34, 41).
TSP1 is secreted by numerous cell types, including
platelets, endothelial cells, macrophages, fibroblasts,
and VSMCs (19, 20, 25, 31, 33, 43). TSP1 expression is
rapidly upregulated on serum or growth factor stimula-
tion of cultured VSMCs (11, 28, 30), and TSP1 protein
and mRNA are elevated with both intimal hyperplasia
and hypercholesterolemia in vivo (26, 42–44, 56). Al-
though TSP1 appears to be important for the prolifera-
tion of VSMCs (27, 29) and fibroblasts (38) it inhibits
endothelial cell growth in vitro (54) and angiogenesis in
vivo (13, 18). However, the molecular mechanisms by
which TSP1 exerts these cell type-specific functions are
not well understood.
Cell cycle progression is facilitated by the sequential
activation of a family of cyclin-dependent kinases (cdks),
which requires their association with specific subunits
called cyclins (15, 32, 49). cdk2 activity is negatively
regulated by members of the growth suppressor family
of cdk inhibitors (CKIs), including p21Cip1/WAF1 (p21)
and p27Kip1 (p27) (14, 16, 37). In the present study we
investigated the molecular pathways through which
TSP1 regulates VSMC proliferation in vitro by using
neutralizing anti-TSP1 monoclonal antibody A4.1. Our
results demonstrate that A4.1-mediated growth arrest
in serum-stimulated VSMCs is associated with the
inhibition of cdk2-dependent kinase activity. Expres-
sion of p21 and its association with cdk2 complexes
were induced on addition of A4.1 antibody to serum-
stimulated VSMCs. Moreover, A4.1 antibody blocked
DNA synthesis in wild-type mouse embryonic fibro-
blasts (MEFs) but not in cells derived from p21-
deficient mice. Together, these data demonstrate that
antibody blockade of TSP1 inhibits cell cycle progres-
sion in a p21-dependent manner, and suggest the
involvement of p21 in TSP1-mediated regulation of
cellular proliferation.
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METHODS
Cell culture. Cells were incubated at 37°C in a humidified
5% CO2-95% O2 atmosphere in medium supplemented with 2
mM L-glutamine, 200 U/ml penicillin, 0.25 mg/ml streptomy-
cin, and serum as indicated. Primary rat aortic VSMCs were
isolated essentially as described (39) and maintained in
DMEM supplemented with 10% fetal bovine serum (FBS,
growth medium). MEFs derived from wild-type and p21-
deficient mice (8) were maintained in DMEM containing 10%
FBS. To enrich the population of cells in G0/G1, cultures were
serum-starved for 3 days in DMEM supplemented with 0.2%
FBS. The C2C12 murine skeletal myoblast cell line was
obtained from American Type Culture Collection. Terminal
differentiation of C2C12 myoblasts maintained in 20%
FBS-DMEM was induced by switching cultures to 2% heat-
inactivated horse serum-DMEM (differentiation medium).
Under these conditions, C2C12 cells permanently exit the cell
cycle and then express differentiation markers (1).
Anti-TSP1 antibody. The mouse monoclonal anti-TSP1
antibody A4.1, which recognizes the trypsin-resistant 70-kDa
core of TSP1 (40), was used in this study. Specificity of this
antibody has been previously established by Western blotting
against samples of whole platelets, serum, and purified
proteins (40). Mouse nonspecific IgM antibody MOPC-104E
(M2521) was used as a control (Sigma Chemical).
[3H]thymidine uptake analysis. Rat VSMCs and MEFs
were plated in 24-well tissue culture plates in DMEM supple-
mented with 10% FBS. Cells were rendered quiescent by
incubation for 3 days in DMEM containing 0.2% FBS and
then cultures were restimulated with growth medium for
16–24 h. When indicated, cells were treated with different
concentrations of anti-TSP1 antibody A4.1 (25–100 µg IgM/ml
of medium). Cells were incubated in growth medium contain-
ing 3 µCi/ml of [3H]thymidine (6.7 Ci/mmol, Dupont NEN) for
the last 4–6 h. Cells were washed three times with PBS and
incubated with cold 10% TCA for 1 h. After we removed the
TCA solution, we rinsed the cells three times with water and
the precipitated material was solubilized with 0.25 N NaOH.
Tritium content in the sodium hydroxide solution was deter-
mined by adding Scintiverse II (Fisher Scientific) and mea-
sured using a Beckman LS 5000TD scintillation counter. The
experiments were performed in triplicate wells. Parallel
cultures of VSMCs and MEFs in 24-well plates were collected
by trypsinization, and the cell numbers were determined
under microscopy with a hemocytometer.
FACS analysis. Rat VSMCs were plated in 100-mm petri
dishes in growth medium and allowed to attach before being
transferred to DMEM containing 0.2% FBS. After 72 h in low
serum, cultures were restimulated by the addition of growth
medium. Cells were trypsinized 24 h after addition of serum,
then washed three times with PBS and fixed in 70% ethanol
overnight at 4°C. DNA was stained with PBS containing 50
µg/ml each of propidium iodide and RNase A (Boehringer
Mannheim). Cell cycle profile was determined at the Core
Flow Cytometry Facility of the Dana Farber Cancer Institute
(Boston, MA) using a Beckton Dickinson Vantage flow cytom-
eter and Lysis II cell cycle analysis software. All experiments
were performed in triplicate.
Western blot analysis, immunoprecipitation/Western blot-
ting, and cdk2-dependent kinase assay. Subconfluent, starva-
tion-synchronized rat VSMCs (in 100-mm plates) were
switched to growth medium with or without the addition of
the indicated amounts of either control IgM or A4.1 anti-TSP1
antibodies for 16 h. Cells were washed three times with cold
PBS, resuspended in 500 µl of lysis buffer (50 mM Tris ·Cl
pH7.4, 150 mM NaCl, 1% NP-40, 1 mM Na3VO4, 2 µg/ml
aproptinin, 2 µg/ml leupeptin, 1 µM phenylmethylsulfonyl
fluoride) and passed through a 26-gauge, 0.5-in. needle
several times. Insoluble material was cleared by centrifuga-
tion at 13,000 rpm for 10 min at 4°C. Protein concentration of
lysates was determined using the Bradford reagent (BioRad).
Protein extract (50 µg) was subjected to electrophoresis on
12% SDS-PAGE and transferred to Immobilon-P (Amer-
sham). Membranes were blocked overnight at 4°C with buffer
A (0.2% Tween-20 in PBS) containing 5% nonfat milk and
then were incubated at room temperature for 3 h with the
indicated primary antibodies diluted in buffer A containing
2% nonfat milk. The following antibodies were used in this
study: anti-p21 (sc-397, 1:200), anti-p27 (sc-528, 1:250), anti-
p53 (sc-99, 1:250), anti-cdk2 (sc-163, 1:500), anti-cyclin A
(sc-751, 1:200), and anti-cyclin E (sc-481, 1:250) (Santa Cruz
Biotechnology). After several washes with buffer A, immuno-
complexes were detected using an enhanced chemilumines-
cence (ECL) detection kit (Amersham Life Science) according
to the recommendations of the manufacturer. Autoradio-
graphs of Western blots were scanned and band intensity was
determined after background subtraction using a densitomet-
ric program (Sigma Gel, Jandel Scientific).
For immunoprecipitation/Western blot-coupled assays, 200
µg of cell extract was precleared with 20 µl of Protein A/G
PLUS-Agarose beads (Santa Cruz Biotechnology) for 30 min
at 4°C, after which samples were incubated with 2 µg of
anti-cdk2 antibodies for 3 h at 4°C. Immunocomplexes were
precipitated with 20 µl of Protein A/G PLUS-Agarose beads at
4°C for 1 h. Pellets were washed three times with lysis buffer
and subjected to Western blotting with anti-cdk2 antibodies
as described above.
Cdk2-dependent kinase assays in cell lysates were per-
formed using histone H1 (Boehringer Mannheim) and
[g-32P]ATP (DuPont NEN) substrates as previously described
(7). The reaction mixtures were separated on 12% SDS-
PAGE. Gels were stained with Coomassie blue (Sigma Chemi-
cal), dried, and autoradiographed.
Statistics. All results are means 6 SE. Statistical signifi-
cance was evaluated using ANOVA followed by Scheffe´’s
procedure for more than two means. P , 0.05 was interpreted
to indicate statistical significance.
RESULTS
Neutralizing A4.1 anti-TSP1 antibody blocks serum-
inducible DNA synthesis in VSMCs. We first investi-
gated the effects of neutralizing A4.1 monoclonal anti-
TSP1 antibody on [3H]thymidine incorporation on serum
restimulation of starvation-synchronized rat VSMCs.
To this end, cells were incubated for 72 h in 0.2%
FBS-DMEM and then stimulated with growth medium
(10% FBS-DMEM) for 24 h, with or without the addi-
tion of A4.1 antibody. As shown in Fig. 1A, serum
restimulation of VSMCs treated with control IgM led to
an approximately sixfold increase in [3H]thymidine
incorporation. However, increasingly higher concentra-
tions of anti-TSP1 antibody reduced serum-inducible
[3H]thymidine uptake, with the highest amount of A4.1
antibody tested completely blocking [3H]thymidine in-
corporation in serum-restimulated VSMCs.
We next performed flow cytometry analysis to further
characterize the effect of A4.1 antibody on VSMC
proliferation. In serum stimulated cultures, ,60 and
30% of the cells were in G1 and S phase, respectively
(Fig. 1B). Whereas treatment of VSMCs with control
IgM did not significantly affect this cell cycle profile,
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addition of A4.1 antibody decreased the cell population
in S phase to ,10% and augmented the population in
G1 to ,81%. Thus, consistent with previous studies
(29), these data demonstrate that neutralization of
TSP1 function in serum-stimulated VSMCs leads to
inhibition of DNA synthesis and accumulation of cells
in G1.
Neutralizing A4.1 anti-TSP1 antibody blocks serum-
inducible cdk2-dependent kinase activity in VSMCs.
Cdk2 function is required for progression through G1
and S phase (15, 32, 49). When assayed in vitro using
anti-cdk2 antibodies and histone H1 as substrate,
cdk2-dependent kinase activity was downregulated in
both starvation-synchronized skeletal muscle cells
(SKMCs) and VSMCs compared with asynchronously
proliferating cells (Fig. 2A, lane Q vs. P). Consistent
with the irreversibility of cell cycle exit in striated
myocytes, serum-restimulated SKMCs disclosed im-
paired induction of cdk2-dependent kinase activity
(lane Q 1 FBS). In marked contrast, serum-restimu-
lated VSMCs upregulated cdk2-dependent kinase activ-
ity to a level similar to that seen in asynchronously
growing cultures, demonstrating that VSMCs can re-
versibly regulate cdk2 function in response to mito-
gens. Because conditions that promote cell growth
arrest were associated with inhibition of cdk2 function,
we sought next to investigate the effect of A4.1 antibody
on cdk2-dependent kinase activity in VSMCs. As shown
in Fig. 2B, VSMCs treated with control IgM efficiently
Fig. 1. Antibody blockade of thrombospondin-1 (TSP1) inhibits serum-
inducible vascular smooth muscle cell (VSMC) proliferation. A: serum-
starved VSMCs (solid bar) were stimulated with DMEM supplemented
with 10% fetal bovine serum (FBS) and control mouse IgM (100 µg/ml,
hatched bar) or with the indicated concentrations of A4.1 anti-TSP1
antibody. After 18 h, [3H]thymidine was added to the medium (3
µCi/ml) and cells were incubated for an additional 6 h. [3H]thymidine
uptake was determined in TCA precipitates in counts/min (cpm).
Each bar represents mean 6 SE of 3 independent experiments.
*Statistically significant differences in A4.1-treated cells vs. cells
treated with control mouse IgM (P , 0.01). B: A4.1 antibody blocked
S-phase entry in serum-stimulated VSMCs. Starvation-synchronized
VSMCs were switched to growth medium (10% FBS) supplemented
with either control IgM or A4.1 antibody (100 µg/ml). After 24 h, cells
were washed with PBS and harvested by trypsinization. Cells were
then fixed in 70% ethanol overnight at 4°C and stained with
propidium iodide. DNA content was analyzed by flow cytometry to
determine cell cycle distribution. Each bar represents mean 6 SE of 3
independent experiments. *Statistically significant differences in
A4.1-treated cells vs. cells treated with control mouse IgM (P , 0.01).
Fig. 2. A4.1 antibody blocks serum-inducible cyclin-dependent ki-
nase 2 (cdk2)-dependent kinase activity. Cell extracts were immuno-
precipitated with anti-cdk2 antibodies, and the kinase activity in the
immunopellets was assayed by using histone H1 and [g-32P]ATP as
substrates. Reaction mixtures were separated onto 12% SDS-PAGE,
and the gels were dried and autoradiographed. Arrows point to
phosphorylated histone H1. A: C2C12 skeletal muscle cells (SKMC)
and VSMCs were maintained in growth medium (lane P, proliferat-
ing) or were serum starved for 3 days (lane Q). Parallel dishes were
also serum-restimulated for 18 h after starvation (lane Q 1 FBS). B:
cell extracts were prepared from starvation-synchronized VSMCs
(0.2% FBS, lane 1) and from cells that had been serum-restimulated
for 16 h with growth medium after serum starvation (10% FBS, lanes
2–4). Serum-stimulated cells were treated with control mouse IgM
(lane 3) or A4.1 anti-TSP1 antibody (lane 4) (100 µg/ml).
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upregulated cdk2-dependent kinase activity on serum
refeeding. In contrast, addition of A4.1 antibody to the
medium blocked the normal serum-dependent induc-
tion of cdk2 activity. Thus inhibition of cdk2 activity
may contribute to the cell cycle inhibitory activity of
anti-TSP1 antibodies in VSMCs.
Neutralizing A4.1 anti-TSP1 antibody abrogates se-
rum-inducible cyclin A and cyclin E expression and
induces p21Cip1/WAF1. Having demonstrated that cell
cycle arrest in A4.1-treated VSMCs is associated with
impaired cdk2 function, we sought to elucidate the
molecular mechanisms underlying this inhibitory ef-
fect. As shown by the Western blot analysis of Fig. 3,
addition ofA4.1 antibody to serum-restimulated VSMCs
had no effect on cdk2 protein levels. Because cdk2
activity during G1 and S phase is induced in part
through its association with cyclin E and cyclin A,
respectively, the effect of A4.1 antibody on the expres-
sion of these regulatory subunits was also studied.
Treatment of serum-restimulated VSMCs with A4.1
antibody blocked serum-inducible expression of cyclin
E and cyclin A (Fig. 3). Thus inhibition of cdk2 activity
by A4.1 is associated with diminished expression of its
cyclin regulatory subunits.
Because cdk2 activity can be negatively regulated
through its association with the inhibitory proteins p21
and p27, we also analyzed the effect of A4.1 antibody on
these growth suppressor molecules. Whereas A4.1 anti-
body did not affect p27 expression, its addition to
serum-restimulated VSMCs markedly upregulated p21
protein levels (Fig. 3). To test whether the induction of
p21 in A4.1-treated VSMCs resulted in an increased
association of p21 with cdk2-containing complexes, cell
lysates were immunoprecipitated with anti-cdk2 anti-
bodies and then the immunopellets were subjected to
Western blot analysis using anti-p21 antibodies. As
shown in Fig. 3, the abundance of p21 associated with
cdk2 was increased by the treatment of cells with A4.1
antibody. The lack of cdk2-bound p21 in serum restimu-
lated cells that were not treated with A4.1 antibody
(Fig. 3, lanes 2 and 3) may be caused by association of
p21 with cdk4-cyclin D1 holoenzymes (23, 36). These
results suggest that upregulation of p21 and its in-
creased association with cdk2, together with dimin-
ished cyclin A and cyclin E expression, may contribute
to growth arrest in VSMCs treated with neutralizing
anti-TSP1 antibody. In these studies, control mouse
IgM had little or no effect on the expression of these cell
cycle regulatory proteins, demonstrating the specificity
of the effects elicited by the A4.1 antibody.
p21 is essential for growth suppression on antibody
blockade of TSP1. The above results suggest that p21
plays an important role on cell cycle arrest in cells
treated with A4.1 antibody. To further investigate the
role of p21 on growth arrest induced on neutralization
of TSP1 function, the effect of A4.1 antibody on [3H]thy-
midine incorporation was tested in MEFs isolated from
wild-type and p21-deficient mice. As shown in Fig. 4,
addition of A4.1 antibody inhibited in a dose-dependent
manner [3H]thymidine incorporation in serum-stimu-
lated wild-type MEFs. In marked contrast, addition of
A4.1 to the culture medium had little or no effect on
[3H]thymidine uptake in serum-stimulated p21-defi-
cient MEFs. These findings demonstrate that p21 is
essential for the cell cycle inhibitory activity of anti-
TSP1 antibody.
DISCUSSION
TSP1 expression is rapidly upregulated on serum or
growth factor stimulation of quiescent VSMCs (11, 28,
30). Moreover, TSP1 protein and mRNA are detected in
VSMCs within atherosclerotic lesions (26, 43, 44, 56)
and during the proliferative response of VSMCs to
vascular injury (42). Consistent with the role of TSP1
as a positive regulator of VSMC proliferation, addition
of neutralizing anti-TSP1 antibodies blocked serum-
inducible VSMC proliferation (29). However, the mecha-
Fig. 3. Antibody blockade of TSP1 inhibits serum-inducible cyclin A
and cyclin E expression and induces p21 protein levels in VSMCs.
Cell extracts (50 µg protein), prepared from VSMCs treated as
indicated in Fig. 2B, were subjected to Western blot analysis using
anti-cdk2, anti-cyclin E, anti-cyclin A, anti-p27, and anti-p21 antibod-
ies. Densitometric analysis was performed to quantify the relative
amount of protein in each band. Results are shown below each lane
and are expressed relative to the amount in serum-starved cells (lane
1 5 100%). To determine the amount of p21 bound to cdk2, 200 µg of
cell extract was immunoprecipitated with anti-cdk2 antibodies.
Immunopellets were resuspended in sample loading buffer and
separated by electrophoresis on 12% SDS-PAGE. After transfer, blot
was subjected to Western blot analysis using anti-p21 antibodies.
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nisms by which TSP1 regulates VSMC growth are not
completely understood. The present study demon-
strates that addition of neutralizing A4.1 antibody to
cultured VSMCs blocked in a dose-dependent manner
the serum-inducible activity of cdk2, a cell cycle regula-
tor that is required for G1- and S-phase progression.
Although cdk2 expression was not affected by the
addition of A4.1 to VSMC cultures, p21 protein level
was induced markedly in A4.1-treated cells. Impor-
tantly, exposure to A4.1 antibody also increased the
interaction of p21 with cdk2 complexes, suggesting that
upregulation of p21 contributes to the repression of
cdk2 activity and cell-cycle arrest on neutralization of
TSP1 function. Further evidence implicating p21 in
growth arrest induced by anti-TSP1 antibody was
provided using MEFs derived from either wild-type or
p21-null mice. Indeed, A4.1 significantly blocked DNA
synthesis in wild-type, but not in p21-null MEFs. These
data together demonstrate that p21 is essential for
A4.1-induced growth arrest, therefore implicating p21
as a downstream effector of TSP1.
Our results show that A4.1 antibody blocks the
normal induction of cyclin A and cyclin E protein
expression normally seen in serum-stimulated VSMCs.
Together with the requirement of these regulatory
subunits for cell cycle progression (14, 16, 17), these
data suggest that inhibition of cyclin A and cyclin E
expression may contribute to growth arrest in VSMCs
exposed to A4.1 antibody. It is noteworthy that serum-
dependent induction of cyclin A promoter activity in
VSMCs and fibroblasts requires a functional E2F bind-
ing site (47, 52). Moreover, the CKIs p16, p21, and p27
can repress transcription of E2F target genes, includ-
ing cyclin A and cdc2 (7, 9, 48, 52, 59), suggesting that
blockade of cyclin A expression in VSMCs treated with
A4.1 antibody may result in part from p21-dependent
transcriptional repression.
The effect of CKIs, ECM components and their
cellular receptors on VSMC proliferation has been the
subject of recent studies. Expression of p21 and p27 in
VSMCs is markedly upregulated after angioplasty at
time points that coincide with the reestablishment of
the quiescent phenotype (7, 53, 58). Moreover, adenovi-
rus-mediated overexpression of p21 (6, 55, 58) and p27
(7) attenuates VSMC hyperplasia after vascular injury
in vivo. Regarding the regulation of CKI expression by
specific components of the ECM, Koyama et al. (22)
reported that polymerized type I collagen inhibits
mitogen-inducible VSMC proliferation in vitro by up-
regulating p27 and p21 levels, whereas monomer colla-
gen supported cell cycle activity (22). Interestingly,
treatment with neutralizing antibodies against a2-
integrins induced p27 and p21 expression and caused
cell cycle arrest in VSMCs grown on monomer collagen
(22). These findings suggest that a2-integrins can sense
changes in collagen structure that modulate VSMC
proliferation through the regulation of CKI expression.
Of note, it has been shown that the TSP receptor CD47
(IAP) can associate with a2b1-integrin and modulate its
function in VSMCs (57). Moreover, TSP-induced VSMC
proliferation in vitro is regulated by b3-integrins, which
are upregulated during injury-induced VSMC hyperpla-
sia in vivo (51). Thus regulation of CKI expression
through specific ECM components (i.e., TSP1) appears
to be an important regulator of VSMC growth.
In summary, the present study demonstrates that
VSMC growth arrest on antibody blockade of TSP1 is
associated with the induction of p21 and repression of
cyclin A and cyclin E expression. Neutralizing A4.1
antibody failed to inhibit cell proliferation in embryonic
fibroblasts derived from p21-deficient mice. These re-
sults suggest that cell cycle arrest in cells treated with
neutralizing A4.1 antibody results, at least in part,
from p21-dependent inhibition of cdk2 function. Taken
together, these data implicate p21 in TSP1-dependent
Fig. 4. p21 is essential for A4.1-dependent cell cycle arrest in mouse
embryonic fibroblasts. MEFS were isolated from wild-type (A) and
p21-deficient (B) mice. Cells were serum-starved by incubation in
0.2% FBS for 72 h. Cultures were switched to growth medium (10%
FBS) supplemented with either control IgM (100 µg/ml, solid bar) or
with the indicated amount of A4.1 antibody. [3H]thymidine was
added to the culture medium 12 h postserum stimulation, cells were
incubated for an additional 4 h, and incorporated label was deter-
mined by TCA precipitation. Values are means 6 SE of 3 experi-
ments.
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regulation of cellular growth. Future studies should
elucidate the molecular mechanisms underlying A4.1-
dependent regulation of p21 expression.
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